Insys Therapeutics Gets a Buy Rating from Jefferies

By Carrie Williams

In a report released today, David Steinberg from Jefferies reiterated a Buy rating on Insys Therapeutics (NASDAQ: INSY), with a price target of $14. The company’s shares opened today at $11.48.

According to, Steinberg is a 4-star analyst with an average return of 5.0% and a 47.3% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Insys Therapeutics is Moderate Buy and the average price target is $14.75, representing a 28.5% upside.

In a report issued on June 1, RBC Capital also reiterated a Buy rating on the stock with a $16 price target.

The company has a one year high of $19.96 and a one year low of $8.70. Currently, Insys Therapeutics has an average volume of 685.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

INSYS Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. INSYS Therapeutics was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.